We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+31.33%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$2.21B
AUM Growth
+$361M
Cap. Flow
-$44.8M
Cap. Flow %
-2.03%
Top 10 Hldgs %
47.06%
Holding
101
New
14
Increased
23
Reduced
22
Closed
13

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$56.1M
2
TSM icon
TSMC
TSM
+$37M
3
GS icon
Goldman Sachs
GS
+$36.8M
4
APO icon
Apollo Global Management
APO
+$30.8M
5
FERG icon
Ferguson
FERG
+$29.7M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$91M
2
AMD icon
Advanced Micro Devices
AMD
+$42.8M
3
WYNN icon
Wynn Resorts
WYNN
+$42.5M
4
NVDA icon
NVIDIA
NVDA
+$38.5M
5
AMZN icon
Amazon
AMZN
+$35.2M

Sector Composition

Rank Sector Weight
1 Healthcare 67.65%
2 Technology 8.34%
3 Consumer Discretionary 5.97%
4 Communication Services 5.67%
5 Industrials 4.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN icon
1
Biohaven
BHVN
$2.16B
$196M 8.85%
4,572,836
+567,236
+14% +$17.6M
ACLX
2
DELISTED
Arcellx
ACLX
$135M 6.11%
2,435,974
-433,993
-15% -$19.6M
RPRX icon
3
Royalty Pharma
RPRX
$26.1B
$109M 4.94%
3,887,702
-208,043
-5% -$5.72M
RARE icon
4
Ultragenyx Pharmaceutical
RARE
$2.65B
$102M 4.6%
2,126,306
+1,446,847
+213% +$56.1M
KURA icon
5
Kura Oncology
KURA
$922M
$99.9M 4.52%
6,946,230
-389,615
-5% -$3.83M
EYPT icon
6
EyePoint Inc
EYPT
$1.02B
$93.8M 4.24%
4,056,847
+564,700
+16% +$6.31M
ITCI
7
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$83.5M 3.78%
1,165,948
-203,901
-15% -$11.7M
INSM icon
8
Insmed
INSM
$23.2B
$83.2M 3.76%
2,684,487
-761,847
-22% -$19.8M
META icon
9
Meta Platforms (Facebook)
META
$1.51T
$77.9M 3.52%
220,183
-60,462
-22% -$19.7M
MSFT icon
10
Microsoft
MSFT
$2.84T
$60.9M 2.75%
161,924
-56,246
-26% -$20M
MRNS
11
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$58.1M 2.63%
5,346,119
+141,177
+3% +$1.06M
AMZN icon
12
Amazon
AMZN
$2.5T
$55.9M 2.53%
368,089
-251,380
-41% -$35.2M
ETNB
13
DELISTED
89bio
ETNB
$54.6M 2.47%
4,888,434
+2,194,030
+81% +$20.2M
APO icon
14
Apollo Global Management
APO
$70.7B
$50.4M 2.28%
540,820
+348,920
+182% +$30.8M
AMD icon
15
Advanced Micro Devices
AMD
$851B
$49.2M 2.22%
333,468
-363,042
-52% -$42.8M
GE icon
16
GE Aerospace
GE
$367B
$45.5M 2.06%
446,294
+6,530
+1% +$605K
GS icon
17
Goldman Sachs
GS
$313B
$42.6M 1.92%
+110,310
New +$36.8M
TSM icon
18
TSMC
TSM
$2.09T
$40.4M 1.83%
+388,232
New +$37M
BSX icon
19
Boston Scientific
BSX
$65.8B
$40.1M 1.81%
694,101
+340,360
+96% +$18.2M
TERN
20
DELISTED
Terns Pharmaceuticals
TERN
$37.9M 1.71%
5,837,126
-204,784
-3% -$1.08M
FULC icon
21
Fulcrum Therapeutics
FULC
$248M
$37.3M 1.68%
5,518,881
-200,000
-3% -$887K
LVS icon
22
Las Vegas Sands
LVS
$30.5B
$36.3M 1.64%
738,163
+95,330
+15% +$4.51M
FERG icon
23
Ferguson
FERG
$44.7B
$34M 1.54%
+176,090
New +$29.7M
ORCL icon
24
Oracle
ORCL
$331B
$34M 1.54%
322,050
+66,739
+26% +$7.28M
KALV
25
DELISTED
KalVista Pharmaceuticals
KALV
$32.9M 1.49%
2,684,005
+263,154
+11% +$2.39M
1
2 3 4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return

Suvretta Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Suvretta Capital Management held 101 positions worth $2.21B, up 20% from $1.85B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Suvretta Capital Management's Q4 2023 filing shows 14 new, 23 increased, 22 reduced and 13 closed positions. Its largest new stake was TSMC: 388,232 shares worth $40.4M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $91M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, up from 63% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Suvretta Capital Management's largest Q4 2023 buy was TSMC: 388,232 shares worth $40.4M.
  • Suvretta Capital Management added most to Ultragenyx Pharmaceutical in Q4 2023, an estimated $56.1M increase.
  • Suvretta Capital Management's biggest Q4 2023 reduction was Advanced Micro Devices, cutting an estimated $42.8M.
  • Suvretta Capital Management fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2023, selling an estimated $91M.
  • Suvretta Capital Management's ten largest holdings make up 47% of its $2.21B portfolio in Q4 2023.
  • Suvretta Capital Management opened 14 new positions and closed 13 in Q4 2023.
  • Suvretta Capital Management's portfolio value rose 20% quarter-over-quarter to $2.21B.

Based on Suvretta Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.